Myelopeptides and their therapeutic use

Details Myelopeptides and their therapeutic use Myelopeptides and their therapeutic use

1999-09-07

2002-10-22

Low, Christopher S. F. (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

6 to 7 amino acid residues in defined sequence

C530S328000, C530S330000, C514S016700, C514S017400

Reexamination Certificate

active

06469137

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to myelopeptides and their therapeutic use.
BACKGROUND OF THE INVENTION
As reported by Mikhailova et al, Immun. Lett. 47:199-203 (1995), and in WO-A-9618652, the bone marrow cells of various animals and humans produce a group of bioregulatory peptides named myelopeptides (MPs). MPs have a wide spectrum of functional activities: immunoregulatory, differentiating and opiate-like. They evoke 2-3-fold stimulation of antibody production to various antigens and correct some immune disorders. MPs influence the differentiation of bone marrow and peripheral blood cells derived from healthy and leukemic donors. They induce terminal differentiation in the leukemic human HL-60 cell line, and show an effect on pain sensitivity.
More specifically, Mikhailova et al report two specific hexapeptides having immunoregulatory properties, i.e. FLGFPT (designated hereinafter as MP-1) (SEQ ID NO: 1) and LVVYPW (designated hereinafter as MP-2) (SEQ ID NO: 2). WO-A-9618652 discloses hexapeptides, having antitumour activity, of the formula Y
1
-Y
2
-Y
3
-Tyr-P-Trp. An example is MP-2.
SUMMARY OF THE INVENTION
Further peptides have been isolated from the supernatant of porcine bone marrow cell culture by means of successive solid phase extraction and HPLC. These novel peptides are of the type comprising 4 to 10 amino-acids including Pro-X and/or X-Pro, X being a hydrophilic amino-acid, and which typically otherwise comprise hydrophobic amino-acids.
The novel peptides have therapeutic utility. For example, they may be used where immunostimulating or antiviral activity is required. In particular, they may induce production of interferon(s), inhibit replication of viruses, including HIV, thereby providing a protective effect in mammals, and increase immune resistance towards bacterial infection.


REFERENCES:
patent: 9501182 (1995-01-01), None
patent: 9530007 (1995-11-01), None
patent: 9610634 (1996-04-01), None
patent: 9618652 (1996-06-01), None
patent: 97/43417 (1997-11-01), None
Tuazon, Biochemistry 36, 16059, 1997.*
Petrov, Rem V. et al. (1997) “Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity”Biopolymers43(2):139-146.
Poloni, Francesca et al. (1995) “Selection of phage-displayed peptides mimicking an extracellular epitope of human MDR1-P-glycoprotein”Physiol. Chem. Phys. Med. NMR27:271-280.
Herman, Z.S. et al. (1980) “Analgesic Activity of Some Tuftsin Analogs” 67(12):613-614.

Affiliated with

Also associated with

Rating

Myelopeptides and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Myelopeptides and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myelopeptides and their therapeutic use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2986477